Heart failure with preserved ejection fraction (HFpEF) occurs due to abnormal relaxation and filling of the left ventricle. Despite the fact that HFpEF accounts for nearly half of all CHF cases, there are no therapies with a proven benefit approved for this patient population. Physicians usually prescribe ACE inhibitors or AIIRAs, beta blockers, and diuretics with the focus to relieve symptoms and manage comorbidities such as hypertension, T2D, or CAD. Unlike HFrEF, calcium-channel blockers can be used in this patient population. The HFpEF Treatment Algorithm provides insight into prescribing patterns of a CHF subpopulation that offers huge commercial opportunity to a drug that is evaluated specifically in this population.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed HFpEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFpEF patients?
- How frequently is each drug class prescribed in the treatment of HFpEF patients?
- What proportion of HFpEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HFpEF patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated HFpEF patients?